Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
291
resultados
Última actualización
15/07/2026 [08:14:00]
Resultados 200 a 225 de 291
Resumen de: WO2024229437A2
Transplantation of inhibitory neuron progenitors rekindles a targeted, time-limited phase of critical period plasticity within recipient brain areas. This restoration of youthful plasticity establishes a therapeutic environment conducive to circuit reorganization, consistently demonstrated to ameliorate cognitive and functional impairments. Remarkably, the mere overexpression of Calb1 in adult inhibitory neurons via viral vectors is adequate to reactivate critical period plasticity without the need for transplantation. Consequently, methodologies and compositions for augmenting Calb1 expression as a therapeutic avenue to reactivate plasticity are described herein.
Resumen de: WO2024228056A1
A universal biomarker array enables the diagnosis and localization of earlier-than- now recognizable disease states as well as increasing the accuracy of diagnosing states of disease(s) in general. The universal biomarker array is formed of a range of mathematical parameters computed from digital tissue images showing tissue details at a cellular level. The universal biomarker array includes one or more novel parameter arrays (namely, a spatial entropy array, a bin array, and/or a quartile array) in combination with one or more state-of-the-art parameter arrays (namely, a pattern array, a distance array, and/or a morphology array) and/or in combination with one or more other parameters. An AI/ML system can be used to analyze the universal biomarker array relative to database-based reference data for early diagnosis and localization of disease processes.
Resumen de: MX2025013978A
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: CN122109545A
0001 本发明公开了CXCL12或CXCR4作为靶点在制备治疗脑小血管疾病的药物中的应用，通过检测CXCL12或CXCR4表达水平，可以预测脑小血管疾病；还公开了CXCL12或CXCR4作为脑小血管疾病诊断标记物的应用，所述CXCL12或CXCR4抑制剂包括盐酸普乐沙福 Plerixafor。本发明揭示了CXCL12或CXCR4作为脑小血管疾病标志物及治疗靶点的新用途，为其抑制剂的临床转化提供了重要依据。
Resumen de: CN122109520A
0001 本申请公开了一种三维立体双极ECL侧向流免疫试纸条及其在免疫检测中的应用，所述的三维立体双极ECL侧向流免疫试纸条包括三维立体双极电极片、侧向流免疫试纸条和连接垫；所述的三维立体双极电极片在下，所述的侧向流免疫试纸条和连接垫在上；所述的三维立体双极电极片采用分层设计，包括电极片层一和电极片层二；所述的电极片层二在下，电极片层一在上；所述电极片层二包括阳性驱动电极；所述的阳性驱动电极包括阳性驱动电极首端、阳性驱动电极尾端及其连接导线。本发明首次设计一种三维立体双极电极片，该电极片包括电极片层一及电极片层二，通过具有粘贴性的背胶结合。这打破了传统双极ECL电极片的缺点，更适合现场快速检测的需求。
Resumen de: CN122103332A
本发明涉及生物医药领域，提供了一种抗磷酸化CREB（Ser133）抗体及其应用。本发明所提供的抗体J20C选自下列至少之一：（a）具有SEQ ID NO:3、4和5所示的轻链CDR序列，以及具有SEQ ID NO:6、7和8所示的重链CDR序列；(b)轻链可变区具有SEQ ID NO:1所示的氨基酸序列，且重链可变区具有SEQ ID NO:2所示的氨基酸序列。此外，本发明还公开了利用此抗体改造的单链抗体，具有较高的灵敏度和特异性。可以作为阿尔茨海默病和癫痫的发生和进展的辅助诊断工具。
Resumen de: WO2024236179A1
The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.
Resumen de: CN122109551A
0001 本发明公开了一种双亲和肽夹心复合物及其构建方法和应用，属于医药技术领域。所述双亲和肽夹心复合物包括特异性识别Aβ40的亲和肽A1和A2以及特异性识别Aβ42的亲和肽P1和P2，所述亲和肽A1和A2的氨基酸序列分别如SEQ ID NO.1和SEQ ID NO.2所示，所述亲和肽P1和P2的氨基酸序列分别如SEQ ID NO.3和SEQ ID NO.4所示。基于此，采用双亲和肽夹心策略构建检测体系，实现对Aβ40和Aβ42的高特异性、高灵敏度检测和区分。本发明筛选出的亲和肽具有亲和力高、特异性强等特点，为临床上阿尔茨海默病的早期诊断、病情监测及相关靶向检测技术的研发提供了新方向和技术支撑。
Resumen de: CN122104715A
本发明公开了针对异质核核糖核蛋白hnRNPA2B1的特异性核酸适配体及应用，属于核酸适配体技术领域。所述hnRNPA2B1适配体为通过体外指数富集配体系统进化（SELEX）从设计的寡核苷酸文库中筛选出来的小单链DNA，由80个核苷酸组成，并且对其靶标具有高亲和力。其可在hnRNPA2B1蛋白的检测方法或检测产品，以及靶向调控的药品或生物制剂中应用，具体的可制成分子探针、作为检测试剂、作为靶向制剂等用于hnRNPA2B1蛋白相关疾病诊断治疗。本发明的hnRNPA2B1适配体具有强的亲和力和特异性，相较抗体具有生产成本低、稳定、合成方便、易于修饰等优势，是疾病诊断治疗中抗体的潜在替代品。
Resumen de: CN122109524A
0001 本发明为基于磁珠和免疫qPCR的ELISA蛋白定量检测方法、试剂盒及其应用，涉及一种用于检测样本中目标分析物的试剂盒及其检测方法，所述试剂盒包括第一试剂和第二试剂，第一试剂包含修饰有针对分析物特异性第一结合剂的磁性颗粒；第二试剂包含针对分析物特异性的第二结合剂，且该第二结合剂与核酸条形码偶联；第一结合剂和第二结合剂结合到目标分析物的不同表位。本发明的试剂盒和检测方法，具有高灵敏度、多重蛋白质检测的优势，尤其适用于低丰度蛋白质生物标志物的检测。
Resumen de: WO2025059486A1
The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).
Resumen de: CN122109511A
0001 本发明属于神经内科疾病的辅助诊断技术领域，公开了一种神经内科用脑脊液取样检测装置，包括中和筒、酸化筒、储气筒与固定架，固定架上设置有存样组件；中和筒内腔设置有进气管，中和筒顶部设置有密封盖，密封盖上与进气管进气端均设置有单向阀；酸化筒顶部与中和筒底部连接，酸化筒底部设置有针管，且针管顶部设置有单向阀，酸化筒侧面的主气管通过连接座与储气筒连接；储气筒通过气筒接口与连接座连接，储气筒内储存有一定量的惰性气体，储气筒内设置有活塞；通过推注及回抽储气筒，即可完成排除空气、抽吸样本、吹扫硫化氢气体等流程，操作简单方便，提供良好的反应环境；中和筒与酸化筒结构简单，可作为一次性耗材使用，无需清洗。
Resumen de: AU2024347751A1
The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.
Resumen de: CN122108723A
本发明涉及一种神经退行性疾病中tau蛋白质变体的富集及鉴定方法。在该方法中，首先设计合成了一种对tau蛋白保守区域具有良好靶向性的识别肽功能化的磁球，将该磁球用于细胞或组织内tau蛋白的富集，然后将所得的tau蛋白样品采用top‑down和middle‑down策略进行神经退行性疾病中tau蛋白质变体的鉴定。
Resumen de: CN122108702A
0001 本发明提供了基于质谱成像技术的动物脑部代谢物鉴定方法及应用，基于质谱成像技术，建立小鼠脑组织切片的内源性代谢物DESI‑MSI分析方法，包括以下步骤：制备代谢物对照品成像样品和大脑组织切片成像样品后，其中多个动物脑组织贴于同一载玻片，采用对照品成像样品进行质谱成像条件优化，采用大脑组织切片成像样品质谱成像分析；结合组织形态学特征将生物样品的图像分割成多个结构区域；针对所述结构区域，进行多元统计分析，获得不同结构区域的差异代谢物；基于母离子和特征子离子轮廓进行代谢物鉴定；用于疾病机制研究和药物对疾病的干预效果评价。
Resumen de: CN122104938A
本发明涉及湖羊FGF1基因及其编码蛋白的应用，属于生物技术领域。湖羊FGF1基因及其编码蛋白在调控湖羊卵巢颗粒细胞氧化应激水平、细胞凋亡或细胞增殖中的应用。本发明首次系统鉴定了绵羊FGF1基因的CDS及蛋白质序列，并分析了其理化性质、翻译后修饰位点、二级与三级结构及系统进化关系，为揭示该基因在氧化应激与细胞命运调控中的作用提供了分子基础。此外，所披露的序列信息及变异数据有助于评估种群遗传多样性，对动物遗传资源的保护、开发与进化研究具有重要科学价值。
Resumen de: AU2024388718A1
Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.
Resumen de: US20260146088A1
0000 The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Resumen de: WO2024229569A1
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
Resumen de: US20260147006A1
0000 The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low α value, or the M1PAM and an acetylcholinesterase inhibitor.
Resumen de: US20260144764A1
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
Resumen de: US20260147005A1
0000 The present disclosure relates to use of tear fluid neuropeptide Y (NPY) level for diagnosis, prognosis, assessment and therapy stratification of corneal nerve damage or loss, corneal neuropathy, corneal neuropathic pain, corneal neuralgia, ocular disease, or peripheral neuropathy.
Resumen de: US20260146040A1
0000 Use of caseinolytic protease P (ClpP) function and/or concentration as a biomarker for predicting the response of a neoplastic disease, preferably cancer or another disease where enhancing ClpP activity may provide a therapeutic benefit, to a compound of Formula I. In other aspects it relates to methods and kits, as well as methods of treatment involving the use of the biomarker.
Nº publicación: WO2026111092A1 28/05/2026
Solicitante:
INDUSTRY ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIV [KR]
\uACBD\uC0C1\uAD6D\uB9BD\uB300\uD559\uAD50\uC0B0\uD559\uD611\uB825\uB2E8
Resumen de: WO2026111092A1
The present invention relates to a novel microRNA for early in vitro diagnosis of Alzheimer's disease and a convergence diagnostic device using same. The novel miRNA of SEQ ID NO: 1 obtained through molecular analysis has a different expression level in the plasma of normal, mild cognitive impairment, and Alzheimer's dementia patient groups, and has the effect of reducing the expression level of proteins associated with mild cognitive impairment and Alzheimer's dementia. Therefore, the present invention has the effect that mild cognitive impairment and Alzheimer's dementia as well as early diagnosis of Alzheimer's dementia can be screened and diagnosed by non-invasively using the novel miRNA present in plasma as a molecular diagnostic marker.
BOPI
Sede Electrónica
